Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo Dainippon Reexamining Midterm Plan Due to Halt of BBI608 Study
Sumitomo Dainippon Pharma may need to revise its FY2013-FY2017 midterm business plan due to the termination of a global PIII study of its colorectal cancer drug BBI608, the president said on August 7. Last year, the company released its business…
To read the full story
Related Article
BUSINESS
- Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
- Eisai, Merck File Lenvima-Welireg Combo for RCC in US
March 3, 2026
- US FDA Accepts Takeda’s Rusfertide Filing, Grants Priority Review
March 3, 2026
- UCB, Daiichi Sankyo to Wind Up Japan Partnership for Vimpat
March 3, 2026
- Ono, AstraZeneca to End Japan Co-Promotion of Forxiga
March 2, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…